Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia
Status:
Terminated
Trial end date:
2020-02-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether nicotine, a drug that activates receptors called
nicotinic acetylcholine receptors in the brain, improves the ability to make or withhold
responses to faces that are either emotionally neutral or emotionally negative. This study
will also test whether the drug affects brain activity while making or withholding responses
using electroencephalography. Previous studies in people with schizophrenia have shown that
more errors in response to negative emotional cues are related to greater likelihood of
impulsive aggressive behavior. Therefore, the aim of this study is to determine whether
nicotine might be a new strategy to reduce aggressive behavior. The investigators' goal is 25
individuals with schizophrenia and 25 healthy controls to complete the study at Vanderbilt.
Phase:
N/A
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborators:
National Institute of Mental Health (NIMH) University of Florida